← Eichor
Study identifier: NCT06758648 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Characterizing the Retinal Microvasculature in Patients with Fabry Disease: a Prospective Observational Study

Condition: Fabry Disease · Endothelial Dysfunction · Microvasculature  ·  Sponsor: Technical University of Munich

PhaseN/A
Planned participants63
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This study aims to gain a deeper understanding of endothelial dysfunction in patients with Fabry disease through a prospective study of the retinal microvasculature and to identify an objective, non-invasive marker to assess disease severity and cardiovascular risk in patients. The main questions addressed are: Do dynamic and static retinal vessel analysis parameters differ from those in healthy individuals? Can these parameters predict cardiovascular and/or Fabry-related events during follow-up? Do these parameters change during follow-up in patients with a non-stable disease?

This description comes directly from the study's public registry record.

Talk to the study team

Christoph Schmaderer, Prof. Dr.  ·  089 4140 5053  ·  christoph.schmaderer@mri.tum.de

Claudia Regenbogen  ·  0894140 5644  ·  claudia.regenbogen@mri.tum.de

Always discuss trial participation with your own doctor first.

Locations (1)

Department of nephrology, Klinikum rechts der IsarMünchen, Bavaria, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06758648